Industry News (Patents)

Patent Issued Covering Treatment of Autoimmune Diseases with Heat Shock Proteins

Published in Vaccine Weekly, January 19th, 2000

Antigenics, L.L.C. announced the issuance of a patent with broad claims covering methods of treatment of autoimmune diseases, such as type 1 diabetes and multiple sclerosis, with heat shock proteins.

The patent is the ninth issued in the United States for which Antigenics has exclusive worldwide rights.

The company's lead product candidate for treatment of autoimmune diseases is the heat shock protein gp96, which has demonstrated efficacy in animal models of type 1 diabetes and multiple sclerosis. Antigenics has also made progress in elucidating the mechanism by which heat shock proteins modulate the immune system to treat these diseases.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-01-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry